1	STATE OF OKLAHOMA
2	1st Session of the 58th Legislature (2021)
3	SENATE BILL 351 By: Hamilton
4	
5	
6	AS INTRODUCED
7	An Act relating to pharmacogenomic testing; requiring
8	licensed practitioner to offer pharmacogenomic test prior to prescription of psychotropic drug; requiring certain disclosures and obtainment of informed
9	consent; directing order and administration of pharmacogenomic test; providing for codification; and
10	providing an effective date.
11	
12	
13	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
14	SECTION 1. NEW LAW A new section of law to be codified
15	in the Oklahoma Statutes as Section 7201 of Title 63, unless there
16	is created a duplication in numbering, reads as follows:
17	A. A licensed practitioner shall, prior to the prescription of
18	any psychotropic drug to a patient, offer to administer a
19	pharmacogenomic test to the patient for the purpose of guiding the
20	decisions of the licensed practitioner with respect to how the
21	patient's genes may react to certain medications.
22	B. The licensed practitioner shall inform the patient that
23	pharmacogenomic tests have not been approved by the Food and Drug
24 27	Administration and shall, to the best of the licensed practitioner's

1	knowledge, inform the patient of the efficacy of pharmacogenomic
2	testing. The licensed practitioner shall obtain the patient's
3	informed consent prior to ordering a pharmacogenomic test. If the
4	practitioner is aware of the cost of the pharmacogenomic test, the
5	practitioner shall provide an estimate to the patient of such cost.
6	C. If a patient provides informed consent to receive a
7	pharmacogenomic test, the licensed practitioner shall order the
8	pharmacogenomic test and administer such test to the patient prior
9	to the prescription of any psychotropic medication.
10	SECTION 2. This act shall become effective November 1, 2021.
11	
12	58-1-1395 DC 1/11/2021 6:14:23 PM
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	